Banook Central Imaging (Banook CI) has been selected by Servier to assess the potential anti-tumor activity of a novel monoclonal antibody based on the RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) and Immune-Related Response criteria (IrRC) in a multicenter Phase I study in patients with breast cancer. The study will also incorporate the use of Tumor Growth Rates (TGR), an assessment that provides the growth rate before and after treatment.
 
Banook CI will use their comprehensive imaging core lab services, including a specialized radiologic review and analysis of all images. Also, Banook’s software will support and automate all the necessary tasks for the follow-up of the radiologic exams, allowing readers to focus on accurate image interpretation and response analysis.
 
“We are delighted to start this new collaboration with Servier,” said Dr. Pascal Voiriot, founder and chief executive officer at Banook CI. “Our customers increasingly attempt to include new methodologies such as TGR or IrRC in their clinical programs. We are always looking for innovative solutions aimed at better and earlier evaluation of the response of patients to the new therapeutic approaches for cancer. Banook CI is setting the bar for the industry.”